Vivos Therapeutics, Inc. VVOS
We take great care to ensure that the data presented and summarized in this overview for Vivos Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VVOS
Top Purchases
Top Sells
About VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Insider Transactions at VVOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2023
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
14,000
+13.93%
|
$0
$0.53 P/Share
|
|
Jun 16
2023
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+9.67%
|
$0
$0.54 P/Share
|
|
Jun 15
2023
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
21
+0.04%
|
$0
$0.5 P/Share
|
|
Jun 14
2023
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+14.81%
|
$0
$0.49 P/Share
|
|
Dec 23
2022
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+29.63%
|
$0
$0.5 P/Share
|
|
Jun 01
2022
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+12.7%
|
$4,000
$1.83 P/Share
|
|
May 31
2022
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+25.4%
|
$16,000
$2.03 P/Share
|
|
Sep 21
2021
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+24.39%
|
$20,000
$4.31 P/Share
|
|
Aug 17
2021
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+32.26%
|
$15,000
$3.0 P/Share
|
|
May 25
2021
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+42.11%
|
$20,000
$5.38 P/Share
|
|
May 25
2021
|
Bradford K. Amman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$5,000
$5.29 P/Share
|
|
Dec 24
2020
|
Bradford K. Amman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$7,000
$7.38 P/Share
|
|
Dec 23
2020
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+40.0%
|
$7,000
$7.27 P/Share
|
|
Dec 11
2020
|
Ronald Kirk Huntsman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$4,000
$8.5 P/Share
|